
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is attractive because its lead asset ML-007C-MA has already shown a differentiated signal in schizophrenia, including a 4.5-point placebo-adjusted PANSS improvement at week 5, a Cohen’s d of 0.37, and prespecified cognitive benefit with a tolerability profile that appears more convenient than Cobenfy. The bigger fundamental upside is the much larger Alzheimer’s disease psychosis opportunity, where there are no approved therapies and the same mechanism could translate into a cleaner, bid-dosed, safety-focused alternative that addresses a meaningful unmet need in an older population. Financially, the company reported a ~$501M pro forma cash position and a $150M PIPE, which management says funds VISTA and ZEPHYR through 2028, giving it enough runway to reach key readouts in 2027 without near-term financing pressure.
Bears say
MapLight Therapeutics is a late-stage follower in a contested muscarinic schizophrenia market, where ZEPHYR only modestly beat placebo on PANSS total (−4.5, ES 0.37, p=0.015) while the QD arm missed, negative symptoms missed, and active-arm discontinuations were 19.9% with notable nausea and vomiting. Its differentiation versus Cobenfy appears limited to food flexibility and convenience, not superior efficacy, so the commercial thesis looks thin as an approved incumbent and multiple competitors already crowd the class. With a required additional Phase 3 study and potential extra QD work, the company’s sales outlook was cut to about $400mn in schizophrenia and $2bn in ADP in 2037E, underscoring execution, approval, and financing risk.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MapLight Therapeutics Inc (MPLT) Forecast
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares